CMC clinical trial packages and phase-appropriate CMC

Building the package

1. Scale the package to the phase. Early phase needs identity, purity, potency, safety related impurities and enough stability to cover the study. Later phases add validated methods, process characterisation and a full stability programme.
2. Start real time stability early. A shelf life claim rests on real time data at the labelled condition. Accelerated data supports it and cannot replace it, so the clock has to start as soon as representative material exists.
3. Validate the bioanalytical methods to the use. Methods supporting clinical samples need documented accuracy, precision, selectivity, stability and a defined range before the samples arrive, not afterwards.
4. Align supply with enrolment. Batch size, shelf life and release timing have to match the enrolment plan. A slow site and a short shelf life together waste material; a fast site outruns supply.
5. Keep comparability in mind at every change. Any change of site, scale or process raises the question of whether the product is the same. Making changes early, while there is little clinical material, is far cheaper than later.
6. Document the reasoning, not just the results. Why a specification was set where it was, and what data supports it, is what a reviewer asks about. Recording it as decisions are made is much easier than reconstructing it.

Stability is the item with the longest clock

Every other part of the package can be accelerated by adding people. Real time stability cannot, because it takes the time it takes, and a shelf life claim is bounded by how early the programme started.

Put representative material on stability as soon as it exists, even if the process will change. The data is not wasted and the alternative is a shorter claim.

Specifications are commitments

A specification filed early becomes a commitment that later batches have to meet, and widening one afterwards requires justification. Setting them from too little data is a common and expensive mistake.

Set them wide enough to be met and narrow enough to be meaningful, and record the data and reasoning behind each one.

Clinical trial therapeutic areas, and why they change the work

The therapeutic area changes almost everything operationally: endpoint and its measurement, trial length, site type and how hard patients are to find, the safety monitoring the protocol needs, and the regulatory precedent the design is judged against. Oncology runs on response and survival endpoints with dose-finding built in; rare disease runs on tiny numbers and natural history comparison; dermatology and ophthalmology on scored scales; infectious disease on time-limited outcomes. A provider's experience is worth asking about by area rather than in general, because the trial's difficulty lives there.

clinical trial site support, and what it covers

Site support is the work that keeps investigator sites able to run the protocol: training and activation, monitoring visits and query resolution, supply of kits and comparator, equipment and its calibration, sample logistics with their temperature records, and the payments and contracts that keep a site willing. It is usually bought as part of a clinical research organisation's service and priced per site per month plus visits. Ask what the escalation path is when a site falls behind, since that is what the service is for.

clinical trial patient recruitment, and what moves it

Recruitment is a funnel, and the levers are site selection, protocol burden, and referral routes rather than advertising spend. Sites with the condition in their own clinic recruit; sites without do not, whatever they promise at feasibility. Inclusion criteria that exclude the typical patient are the commonest self-inflicted delay, and a screen failure rate above a third usually points at the protocol rather than at the sites. Where recruitment is bought as a service, the metric to agree is randomised patients rather than referrals.

clinical trial patient support, and what it includes

Patient support covers what makes participation possible: travel and expenses, home nursing or a home visit where a protocol allows it, transport of samples, help with scheduling around work and care, and clear materials in the participant's own language. It is bought as a service and is judged on retention rather than on recruitment, since a trial that recruits well and loses a fifth of its participants has a bigger problem than a slow start. Ethics approval covers what may be offered, and that boundary is checked before it is promised.

Common questions

How complete does an early package need to be?

Phase appropriate: enough to establish identity, purity, potency and safety for the study duration. Regulators expect it to grow, and over-filing early commits you to specifications you may want to change.

Can accelerated data support a shelf life?

It supports and does not replace real time data at the labelled condition. Shelf life claims are extended as real time data accumulates, which is why the programme starts as early as possible.

When should bioanalytical methods be validated?

Before clinical samples are analysed. Retrospective validation of a method already used is far weaker and occasionally forces reanalysis of stored samples that may no longer be stable.

Browse by service class

• Compare Gene synthesis on advertised prices